No abstract

No abstract

No abstract

Abstract-Most of today's processors include vector units that have been designed to speedup single threaded programs. Although vector instructions can deliver high performance, writing vector code in assembly language or using intrinsics in high level languages is a time consuming and error-prone task. The alternative is to automate the process of vectorization by using vectorizing compilers.This paper evaluates how well compilers vectorize a synthetic benchmark consisting of 151 loops, two application from Petascale Application Collaboration Teams (PACT), and eight applications from Media Bench II. We evaluated three compilers: GCC (version 4.7.0), ICC (version 12.0) and XLC (version 11.01). Our results show that despite all the work done in vectorization in the last 40 years 45-71% of the loops in the synthetic benchmark and only a few loops from the real applications are vectorized by the compilers we evaluated.

Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy, with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and PaCa progression. Activated PSCs release hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-1) that induce PaCa proliferation, metastasis and resistance to chemotherapy. We demonstrate for the first time that the metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), is a potent inhibitor of the PaCa-PSC cross-talk, leading to inhibition of HGF and IGF-1 signaling. NDRG1 also potently reduced the key driver of PaCa metastasis, namely GLI1, leading to reduced PSC-mediated cell migration. The novel clinically trialed anticancer agent, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), which upregulates NDRG1, potently de-sensitized PaCa cells to ligands secreted by activated PSCs. DpC and NDRG1 also inhibited the PaCa-mediated activation of PSCs via inhibition of sonic hedgehog (SHH) signaling. In vivo, DpC markedly reduced PaCa tumor growth and metastasis more avidly than the standard chemotherapy for this 2 of 19 | GELETA ET AL.